Article from Slotman in the JCO this week:
This is a report from the PCI trial in extensive stage SCLC, looking at the quality of life in both arms. At 3 months, fatigue and hair loss were worse in the treatment arm, with a number of other scales slightly worse in the PCI arm as well.
Of course this is in light of the overall survival benefit of the treatment as reported in the NEJM. And one must also keep in mind selection bias in all of these QOL reports, in that if patients felt to ill to complete the form, no data is captured.
Still this is an interesting report and gives us data to base consent conversations upon.